1.09
2.68%
-0.03
시간 외 거래:
1.08
-0.01
-0.92%
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire Inc.
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Zacks Investment Research
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Zacks Investment Research
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga
Sizing Your Penny Stocks Position, 3 Tips
PennyStocks
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Gold Gains 1%; Walgreens Narrows Earnings Forecast
Benzinga
US Stocks Flat; Initial Jobless Claims Fall To 210,000
Benzinga
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
GlobeNewswire Inc.
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
GlobeNewswire Inc.
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
GlobeNewswire Inc.
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
GlobeNewswire Inc.
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Benzinga
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
GlobeNewswire Inc.
자본화:
|
볼륨(24시간):